This retrospective study analyzed frailty progression in metastatic spine disease (MSD) patients treated with stereotactic body radiation therapy (SBRT) using a modified frailty index (MSTFI-7). Findings reveal that frailty status evolves over time post-spinal metastasis diagnosis, with specific comorbidities contributing variably to frailty severity and progression.
Background
Frailty is a multidimensional syndrome indicating decreased physiological reserves and increased vulnerability to adverse outcomes. It has been widely used to predict clinical outcomes across various medical fields, including oncology and surgery. In metastatic spine disease, frailty assessment is emerging as a critical tool for prognostication and treatment planning. However, interventions targeting frailty remain limited, highlighting the need for better understanding of frailty dynamics in this population.
Data Highlights
Timepoint
Frailty Status Categories
Score Range
Initial Cancer Diagnosis
Not frail, Mild, Moderate, Severe
0, 1, 2, ≥3
Spinal Metastasis Diagnosis
Not frail, Mild, Moderate, Severe
0, 1, 2, ≥3
Every 4 months up to 2 years post-SM diagnosis
Not frail, Mild, Moderate, Severe
0, 1, 2, ≥3
Key Findings
Frailty was assessed using MSTFI-7, focusing on seven comorbidities excluding hospital admission and surgical approach.
Frailty scores were categorized as Not frail (0), Mild (1), Moderate (2), and Severe (≥3).
Frailty status was tracked longitudinally at initial cancer diagnosis, spinal metastasis diagnosis, and every 4 months for 2 years post-diagnosis.
Dynamic changes in frailty were observed, with some patients showing progression or improvement over time.
Specific comorbidities such as anemia, chronic lung disease, and pulmonary circulation disorders contributed variably to overall frailty scores.
Mixed-effect modeling was employed to identify patient variables strongly associated with frailty progression.
Clinical Implications
Regular frailty assessment using standardized indices like MSTFI-7 can provide valuable prognostic information in MSD patients undergoing SBRT. Understanding the evolving nature of frailty and its contributing factors may guide personalized treatment planning and identify patients who could benefit from targeted interventions to improve resilience. Incorporating frailty evaluation into routine oncologic care could enhance risk stratification and optimize clinical outcomes.
Conclusion
Frailty in metastatic spine disease patients is a dynamic condition influenced by multiple comorbidities and evolves over the course of oncologic treatment. Systematic frailty monitoring offers a promising approach to improve prognostication and tailor therapeutic strategies in this vulnerable population.
References
De la Garza Ramos et al. -- Development of the Metastatic Spinal Tumor Frailty Index
Global Leadership Initiative on Malnutrition -- Malnutrition Assessment Criteria
by Oludotun Ogunsola, Edward S. Harake, Sean Smith, Michael Albdewi, Varun Kathawate, Sebele Ogunsola, William Jackson, Joseph Evans, Vikram Chakravarthy, Nicholas Szerlip
Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties
